# Sample Metadata Template for miRNA Oxidation Research
# ============================================================================
# This file defines sample groups and metadata for flexible pipeline analysis
# ============================================================================
# 
# REQUIRED COLUMNS:
# - sample_id: Must exactly match column names in your data file
# - group: Condition/group name (e.g., "Disease", "Control", "Treatment", "ALS", etc.)
#           You can use ANY group names - pipeline is flexible!
#
# OPTIONAL COLUMNS (for advanced analyses):
# - batch: Batch or run identifier (for batch effect analysis)
# - age: Age of the subject (for confounder analysis)
# - sex: Sex of the subject (M/F or Male/Female, for confounder analysis)
# - timepoint: Time point (e.g., 0d, 7d, 14d, 1m, 3m, 6m, 1y)
# - subject_id: Unique identifier for each subject
# - diagnosis: Clinical diagnosis
# - treatment: Treatment received
# - notes: Additional notes
#
# IMPORTANT:
# - sample_id must EXACTLY match the column names in your data CSV file
# - You need at least 2 groups for comparison
# - Each group needs at least 2 samples
# - Group names can be anything (not limited to "ALS"/"Control")
#
# EXAMPLE FOR ALS vs CONTROL:
# sample_id,group,batch,age,sex
# Magen-ALS-enrolment-bloodplasma-SRR13934430,ALS,Batch1,65,M
# Magen-control-control-bloodplasma-SRR14631747,Control,Batch1,62,F
#
# EXAMPLE FOR ANY DISEASE:
# sample_id,group,batch,age,sex
# Sample1,Parkinson,Batch1,70,M
# Sample2,Healthy,Batch1,68,F
# Sample3,Alzheimer,Batch1,75,F
# ============================================================================

sample_id	group	timepoint	subject_id	batch	age	sex	diagnosis	treatment	notes
sample_001	ALS	0d	ALS_001	batch_1	65	M	ALS	None	Baseline sample
sample_002	ALS	7d	ALS_001	batch_1	65	M	ALS	None	1 week follow-up
sample_003	ALS	14d	ALS_001	batch_1	65	M	ALS	None	2 week follow-up
sample_004	Control	0d	CTRL_001	batch_1	62	F	Healthy	None	Healthy control
sample_005	Control	7d	CTRL_001	batch_1	62	F	Healthy	None	1 week follow-up
sample_006	Control	14d	CTRL_001	batch_1	62	F	Healthy	None	2 week follow-up
sample_007	Treatment	0d	TREAT_001	batch_2	58	M	ALS	Drug_A	Pre-treatment
sample_008	Treatment	7d	TREAT_001	batch_2	58	M	ALS	Drug_A	1 week post-treatment
sample_009	Treatment	14d	TREAT_001	batch_2	58	M	ALS	Drug_A	2 weeks post-treatment
sample_010	ALS	0d	ALS_002	batch_2	71	F	ALS	None	Baseline sample
sample_011	ALS	7d	ALS_002	batch_2	71	F	ALS	None	1 week follow-up
sample_012	ALS	14d	ALS_002	batch_2	71	F	ALS	None	2 week follow-up
sample_013	Control	0d	CTRL_002	batch_2	69	M	Healthy	None	Healthy control
sample_014	Control	7d	CTRL_002	batch_2	69	M	Healthy	None	1 week follow-up
sample_015	Control	14d	CTRL_002	batch_2	69	M	Healthy	None	2 week follow-up
sample_016	Treatment	0d	TREAT_002	batch_3	63	F	ALS	Drug_B	Pre-treatment
sample_017	Treatment	7d	TREAT_002	batch_3	63	F	ALS	Drug_B	1 week post-treatment
sample_018	Treatment	14d	TREAT_002	batch_3	63	F	ALS	Drug_B	2 weeks post-treatment
sample_019	ALS	0d	ALS_003	batch_3	67	M	ALS	None	Baseline sample
sample_020	ALS	7d	ALS_003	batch_3	67	M	ALS	None	1 week follow-up
sample_021	ALS	14d	ALS_003	batch_3	67	M	ALS	None	2 week follow-up
sample_022	Control	0d	CTRL_003	batch_3	64	F	Healthy	None	Healthy control
sample_023	Control	7d	CTRL_003	batch_3	64	F	Healthy	None	1 week follow-up
sample_024	Control	14d	CTRL_003	batch_3	64	F	Healthy	None	2 week follow-up
sample_025	Treatment	0d	TREAT_003	batch_4	59	M	ALS	Drug_A	Pre-treatment
sample_026	Treatment	7d	TREAT_003	batch_4	59	M	ALS	Drug_A	1 week post-treatment
sample_027	Treatment	14d	TREAT_003	batch_4	59	M	ALS	Drug_A	2 weeks post-treatment
sample_028	ALS	0d	ALS_004	batch_4	73	F	ALS	None	Baseline sample
sample_029	ALS	7d	ALS_004	batch_4	73	F	ALS	None	1 week follow-up
sample_030	ALS	14d	ALS_004	batch_4	73	F	ALS	None	2 week follow-up


